ACRS
Aclaris TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
If ATI-052 and bosakitug both continue to advance, the market can re-rate Aclaris on pipeline optionality while the reported cash runway through end-2028 reduces immediate financing pressure [#8-K-2026-05-07].
Posture
Constructive
Lead driver
Momentum
What changed
News driver: Aclaris Therapeutics ( NASDAQ : ACRS ) Sets New 12 - Month High Following Earnings Beat.
What can break
Clinical execution risk: ATI-052 and bosakitug both need clean efficacy/safety data to justify further rerating.
Momentum
88
Value
41
Sentiment
68
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.80 · Bull $8.30 · Bear $2.70
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-27 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $8.94
Why
Momentum88 · Δ7d -2.8
Value41 · Δ7d +0.1
Sentiment68 · Δ7d -34.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
88
34% active weight
Current posture
7d trendFlat
Δ7d
-2.8
Δ21d
-4.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
68
33% active weight
Current posture
7d trendSoftening
Δ7d
-34.9
Δ21d
+36.7
Why this grade
Composite grade A. Momentum 88.1 / Value 41.1 / Sentiment 68.4
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$606.14M
Beta
0.87
Shares Out
108.35M
P/E (TTM) · Derived
-10.6
P/S (TTM)
18.24
P/FCF (TTM) · Derived
-8.13
Rev YoY
-24.1%
EPS YoY
-12.1%
Gross Margin
+4.0%
Op Margin
-973.9%
Net Debt
-$113.59M
Current Ratio
3.92
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology